User:Shrinwanti Ghosh/sandbox AromataseInhibitor

In the year 2001, the ovulation induction drug aromatase inhibitors (AIs) were introduced. Some research has found AIs to increase live birth and pregnancy rates in sub-fertile, anovulatory polycystic ovary syndromic women. AIs are highly active for the therapy of estrogen receptor-positive breast cancer in postmenopausal women. AIs work by reducing systemic estrogen concentrations through inhibiting aromatase enzyme-mediated switch of androgens to estrogens.

Benign proliferation of the breast glandular tissue of boys known as Gynecomastia. Aromatase plays an essential role in the production of estrogens in men. AIs used to prevent gynecomastia. AIs, help to increase gonadotropin secretion and accelerate Leydig and Sertoli cell function.

There are four aromatase inhibitors are available: letrozole, anastrozole, exemestane, and testolactone.

1.Femara (Pro) Generic name: letrozole

2.Arimidex (Pro) Generic name: anastrozole 3.Aromasin (Pro) Generic name: exemestane

4.Teslac (Pro) Generic name: testolactone